Bristi Basu: Pleased That the CRUK Pancreatic Cancer Conference Was Such a Barnstorming Success!
Bristi Basu, Honorary Consultant Medical Oncologist at University of Cambridge, shared a post on LinkedIn: “I’m so pleased that the inaugural Cancer Research UK (CRUK) Pancreatic Cancer Conference…
Read the full articleYou might also wanna read
EU-funded Czech cancer prevention centre in Brno leverages AI and early detection to tackle Europe's growing oncology burden
EU Health Commissioner Várhelyi described the state-of-the-art cancer centre as a potential model for Europe
euractiv.com·1mo agoResearch Spotlight: Highlights from the ASCO Annual Meeting and Beyond
Jun 24, 2026 - By Anna Berkenblit, MD, MMSc Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit , PanCAN’s Chie
Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors a
Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patien
consent.youtube.com·15d ago
Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors a
Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patien
consent.youtube.com·15d agoMitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors a
Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patien
consent.youtube.com·15d ago
ASCO Day 3: Pancreatic cancer advance earns standing ovation; Akeso and Summit face disappointment
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
statnews.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.